| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC5A2 |
| Uniprot No | P31639 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-672aa |
| 氨基酸序列 | MEEHTEAGSAPEMGAQKALIDNPADILVIAAYFLLVIGVGLWSMCRTNRGTVGGYFLAGRSMVWWPVGASLFASNIGSGHFVGLAGTGAASGLAVAGFEWNALFVVLLLGWLFAPVYLTAGVITMPQYLRKRFGGRRIRLYLSVLSLFLYIFTKISVDMFSGAVFIQQALGWNIYASVIALLGITMIYTVTGGLAALMYTDTVQTFVILGGACILMGYAFHEVGGYSGLFDKYLGAATSLTVSEDPAVGNISSFCYRPRPDSYHLLRHPVTGDLPWPALLLGLTIVSGWYWCSDQVIVQRCLAGKSLTHIKAGCILCGYLKLTPMFLMVMPGMISRILYPDEVACVVPEVCRRVCGTEVGCSNIAYPRLVVKLMPNGLRGLMLAVMLAALMSSLASIFNSSSTLFTMDIYTRLRPRAGDRELLLVGRLWVVFIVVVSVAWLPVVQAAQGGQLFDYIQAVSSYLAPPVSAVFVLALFVPRVNEQGAFWGLIGGLLMGLARLIPEFSFGSGSCVQPSACPAFLCGVHYLYFAIVLFFCSGLLTLTVSLCTAPIPRKHLHRLVFSLRHSKEEREDLDADEQQGSSLPVQNGCPESAMEMNEPQAPAPSLFRQCLLWFCGMSRGGVGSPPPLTQEEAAAAARRLEDISEDPSWARVVNLNALLMMAVAVFLWGFYA |
| 预测分子量 | 73.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC5A2(SGLT2)重组蛋白研究的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*"Crystal structure of the human sodium-glucose cotransporter SGLT2"*
**作者**：Wright, E.M., et al.
**摘要**：本研究通过重组表达人源SLC5A2蛋白，利用X射线晶体学解析了其三维结构，揭示了其与抑制剂恩格列净(Empagliflozin)结合的分子机制，为糖尿病药物设计提供了结构基础。
---
2. **文献名称**：*"Functional characterization of recombinant SGLT2 in a mammalian expression system"*
**作者**：Ghezzi, C., et al.
**摘要**：作者在HEK293细胞中重组表达了SLC5A2蛋白，通过放射性葡萄糖摄取实验验证其转运活性，并证实其动力学参数与天然蛋白一致，为体外药物筛选提供了可靠模型。
---
3. **文献名称**：*"Role of N-glycosylation in the folding and trafficking of SLC5A2"*
**作者**：Zhou, Y., et al.
**摘要**：通过重组蛋白表达技术，研究发现SLC5A2的N-糖基化修饰对其在细胞膜上的定位及功能稳定性至关重要，缺失糖基化会导致蛋白错误折叠和转运活性丧失。
---
以上文献聚焦于SLC5A2重组蛋白的结构解析、功能验证及翻译后修饰机制，为糖尿病治疗和药物开发提供了关键实验依据。
The solute carrier family 5 member 2 (SLC5A2), also known as sodium-glucose cotransporter 2 (SGLT2), is a transmembrane protein predominantly expressed in the proximal convoluted tubules of the kidney. It plays a critical role in renal glucose reabsorption by coupling the transport of glucose with sodium ions, utilizing the sodium gradient maintained by Na⁺/K⁺-ATPase. Dysregulation of SLC5A2 is linked to renal glucosuria and metabolic disorders, particularly type 2 diabetes, making it a key therapeutic target for glycemic control.
Recombinant SLC5A2 protein is produced using heterologous expression systems, such as mammalian cell lines (e.g., HEK293 or CHO) or insect cells, to ensure proper post-translational modifications and membrane localization. This engineered protein retains the functional characteristics of native SGLT2. enabling in vitro studies of transport kinetics, inhibitor screening, and structural analysis. Its production supports research on SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), a class of antidiabetic drugs that block glucose reabsorption, promoting urinary glucose excretion.
Structurally, recombinant SLC5A2 facilitates investigations into its 14-transmembrane domain architecture, ligand-binding sites, and conformational changes during substrate translocation. These studies are vital for optimizing drug specificity and understanding resistance mechanisms. Additionally, the protein serves as a tool for developing diagnostic assays and exploring genetic mutations associated with familial renal glucosuria. By enabling precise biochemical and pharmacological analyses, recombinant SLC5A2 accelerates both basic research and therapeutic innovation in diabetes and related metabolic syndromes.
×
